Beaufour Ipsen: Gearing up to Go Public

Family-owned Beaufour Ipsen has kept its cards to its chest for most of its 70-year history. Now, though, France's third largest independent pharmaceutical company is gearing up for a big US push-and to go public.

Between 1929 and 1998, Beaufour Ipsen SA was run by just two generations—founder Dr. Henri Beaufour, then his two sons, Albert and Gérard. Until the late 80s, Beaufour was as French as they came, with the vast majority of sales in its home territory. The group was best known for its series of products derived from natural sources, such as clay-based gastrointestinal treatments Smetca, Bedelix and Actapulgite, and gingko biloba plant extracts (sold as Tanakan and Ginkor).

Over the last ten years, however, Beaufour has built a lot more. The first visible signs of change came in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.